NEW YORK, Jan. 5, 2026 /PRNewswire/ — Ro, the leading direct-to-patient healthcare company, announced today that it is working with Novo Nordisk on the nationwide launch of the new Wegovy® pill. Patients today can come to ro.co for the easiest way to access the first and only oral GLP-1 weight loss medication at the lowest available cash pay price. Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer’s direct-to-patient expansion to date.

Read more here.